NeuroXT Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Employees
  • 22

Employees

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 13

NeuroXT General Information

Description

Developer of precision diagnosis software intended to predict molecular pathology values. The company uses magnetic resonance imaging (MRI) images to analyze a specific treatment drug's effects or side effects on the patient to determine suitability, enabling the healthcare sector to benefit from precision treatment for degenerative brain diseases based on various image analysis experiences.

Contact Information

Website
www.neuroxt.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Seongsu SK V1 Center, Building 1, Room 601
  • 48, Achasan-ro 17-gil, Seongdong-gu
  • Seoul, 04799
  • South Korea
+82
Primary Industry
Decision/Risk Analysis
Corporate Office
  • Seongsu SK V1 Center, Building 1, Room 601
  • 48, Achasan-ro 17-gil, Seongdong-gu
  • Seoul, 04799
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NeuroXT Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Early Stage VC 09-Mar-2025 Completed Generating Revenue
5. Accelerator/Incubator 01-Jan-2023 Completed Generating Revenue
4. Early Stage VC (Series A) 01-Dec-2022 Completed Generating Revenue
3. Accelerator/Incubator 01-Jul-2022 Completed Generating Revenue
2. Seed Round 01-Jun-2022 Completed Generating Revenue
1. Accelerator/Incubator Completed Generating Revenue
To view NeuroXT’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

NeuroXT Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NeuroXT Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
LG Holding Company Minority
Medinno Partners Venture Capital Minority
Samsung Venture Investment Corporate Venture Capital Minority
KU Startup Accelerator/Incubator
DAYLI Partners Venture Capital Minority
You’re viewing 5 of 13 investors. Get the full list »

NeuroXT FAQs

  • When was NeuroXT founded?

    NeuroXT was founded in 2022.

  • Where is NeuroXT headquartered?

    NeuroXT is headquartered in Seoul, South Korea.

  • What is the size of NeuroXT?

    NeuroXT has 22 total employees.

  • What industry is NeuroXT in?

    NeuroXT’s primary industry is Decision/Risk Analysis.

  • Is NeuroXT a private or public company?

    NeuroXT is a Private company.

  • What is NeuroXT’s current revenue?

    The current revenue for NeuroXT is .

  • Who are NeuroXT’s investors?

    LG, Medinno Partners, Samsung Venture Investment, KU Startup, and DAYLI Partners are 5 of 13 investors who have invested in NeuroXT.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process